Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on Thursday, May 4, 2017

BOSTON, April 18, 2017 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that it will host a conference call and webcast on Thursday, May 4, 2017 at 8:00 a.m. ET to discuss its first quarter 2017 financial results and provide corporate updates.

To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 8810002. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.

Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.

About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.

Keryx Biopharmaceuticals Contact:

Lora Pike
Senior Director, Investor Relations & Corporate Communications
T: 617.466.3511
[email protected]